Session 5: Sequencing Therapies for Multiple Myeloma in the Era of Bispecific Antibodies

home / training-academy / sequencing-therapies-for-multiple-myeloma-in-the-era-of-bispecific-antibodies

A panel of experts discusses recent updates in the role of bispecific antibodies in the treatment of multiple myeloma and the optimal sequencing strategies.

EP. 1: Patient Case 1: A 68-Year-Old with R/R MM Treated with Teclistamab

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

May 24th 2023

Jack Khouri, MD, presents the case of a 68-year-old patient with relapsed/refractory multiple myeloma and extramedullary disease treated with teclistamab.

EP. 2: Selecting Patients with MM for Teclistamab and Optimal Sequencing

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

May 24th 2023

The panel discusses their potential treatment approaches for the presented patient case and how they select patients with relapsed/refractory MM for teclistamab and optimally sequence therapies.

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777